OraSure Technologies (NASDAQ:OSUR) was downgraded by research analysts at TheStreet from a “b” rating to a “c+” rating in a report released on Thursday.

Several other analysts also recently weighed in on the company. Zacks Investment Research downgraded OraSure Technologies from a “strong-buy” rating to a “hold” rating in a report on Wednesday. ValuEngine upgraded OraSure Technologies from a “hold” rating to a “buy” rating in a research note on Tuesday. BidaskClub upgraded OraSure Technologies from a “strong sell” rating to a “sell” rating in a research note on Wednesday, October 24th. Raymond James reiterated a “mkt perform” rating on shares of OraSure Technologies in a research note on Tuesday, October 23rd. Finally, Stephens lowered OraSure Technologies from an “overweight” rating to an “equal weight” rating in a research note on Monday, July 16th. One analyst has rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the company. The company has an average rating of “Hold” and an average target price of $20.50.

OSUR stock opened at $13.01 on Thursday. The stock has a market capitalization of $900.47 million, a P/E ratio of 25.51, a PEG ratio of 3.46 and a beta of 1.52. OraSure Technologies has a 1-year low of $12.50 and a 1-year high of $22.22.

OraSure Technologies (NASDAQ:OSUR) last released its quarterly earnings data on Wednesday, November 7th. The medical instruments supplier reported $0.13 earnings per share for the quarter, beating the consensus estimate of $0.11 by $0.02. The firm had revenue of $45.90 million during the quarter, compared to the consensus estimate of $44.50 million. OraSure Technologies had a return on equity of 6.68% and a net margin of 9.49%. The firm’s quarterly revenue was up 8.5% on a year-over-year basis. During the same period in the previous year, the company posted $0.09 earnings per share. On average, research analysts anticipate that OraSure Technologies will post 0.34 EPS for the current fiscal year.

In other OraSure Technologies news, Director Charles W. Patrick sold 8,000 shares of OraSure Technologies stock in a transaction dated Monday, August 27th. The stock was sold at an average price of $16.29, for a total value of $130,320.00. Following the transaction, the director now owns 54,298 shares in the company, valued at $884,514.42. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 2.90% of the stock is owned by insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Trexquant Investment LP purchased a new position in OraSure Technologies in the third quarter valued at about $229,000. BlackRock Inc. grew its stake in shares of OraSure Technologies by 5.9% during the third quarter. BlackRock Inc. now owns 8,979,357 shares of the medical instruments supplier’s stock worth $138,732,000 after acquiring an additional 498,527 shares during the last quarter. Thomson Horstmann & Bryant Inc. purchased a new stake in shares of OraSure Technologies during the third quarter worth about $439,000. Campbell & CO Investment Adviser LLC purchased a new stake in shares of OraSure Technologies during the third quarter worth about $187,000. Finally, Asymmetry Capital Management L.P. purchased a new stake in shares of OraSure Technologies during the third quarter worth about $2,773,000. Institutional investors own 92.00% of the company’s stock.

About OraSure Technologies

OraSure Technologies, Inc, together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, OSUR and DNAG. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests.

Featured Story: How to Use a Moving Average for TradingĀ 

Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.